EAST.V - EastWest Bioscience Inc.
| Previous Close | 0.0300 |
| Open | 0.0300 |
| Bid | 0.0300 x 0 |
| Ask | 0.0350 x 0 |
| Day's Range | 0.0300 - 0.0300 |
| 52 Week Range | 0.0200 - 0.1550 |
| Volume | 7,000 |
| Avg. Volume | 249,746 |
| Market Cap | 2.447M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0570 |
| Earnings Date | Jan 26, 2020 - Jan 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
EastWest Issues Fourth Bi-Weekly Status Report Regarding Management Cease-Trade Order
In its initial default announcement of November 29, 2019 (the "Default Notice"), the Corporation announced the delay in the filing of its audited annual financial statements for the year ended July 31, 2019 (the "2019 Annual Financial Statements") and related management discussion and analysis and certifications (collectively, the "Annual Filings") by the filing deadline of November 28, 2019. The Company subsequently provided bi-weekly default status reports on December 12, 2019, December 27, 2019 and January 10, 2020.
- ACCESSWIRE
EastWest Bioscience to Close Debt Settlement Arrangement
The Corporation will settle outstanding indebtedness to an arm's length creditor in the amount of $13,750 in exchange for 275,000 common shares of the Corporation at a price of $0.05 per common share. EastWest Bioscience is a vertically integrated wellness corporation with the infrastructure to become a global giant in the Hemp & CBD consumer health market. Since it was founded in 2016, EastWest continues to grow as a high-quality producer, manufacturer and distributor of multiple lines of premium health and hemp products.
- ACCESSWIRE
EastWest Issues Third Bi-weekly Status Report Regarding Management Cease-Trade Order
In its initial default announcement of November 29, 2019 (the "Default Notice"), the Corporation announced the delay in the filing of its audited annual financial statements for the year ended July 31, 2019 (the "2019 Annual Financial Statements") and related management discussion and analysis and certifications (collectively, the "Annual Filings") by the filing deadline of November 28, 2019. The Company subsequently provided bi-weekly default status reports on December 12, 2019 and December 27, 2019.
- ACCESSWIRE
EastWest Issues Second Bi-Weekly Status Report Regarding Management Cease-Trade Order
VANCOUVER, BC / ACCESSWIRE / December 27, 2019 / EastWest Bioscience Inc. ("EastWest" or the "Corporation") provides this bi-weekly default status report in accordance with National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"). In its initial default announcement of November 29, 2019 (the "Default Notice"), the Corporation announced the delay in the filing of its audited annual financial statements for the year ended July 31, 2019 (the "2019 Annual Financial Statements") and related management discussion and analysis and certifications (collectively, the "Annual Filings") by the filing deadline of November 28, 2019. The Company subsequently provided a bi-weekly default status report on December 12, 2019.
- ACCESSWIRE
EastWest Bioscience to Acquire Shares of 1123573 BC Ltd. and Orchard Valley Naturals Ltd.
VANCOUVER, BC / ACCESSWIRE / December 18, 2019 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that it has entered a share purchase agreement (the "Agreement") with Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp. (collectively, the "Sangster Parties") for the purchase of shares of 1123573 BC Ltd. ("573") and Orchard Valley Naturals Inc. ("Valley"). Completion of the Agreement is subject to the approval of the TSX Venture Exchange. EastWest currently holds 50% of the shares of 573 and Valley.
- ACCESSWIRE
EastWest Issues Bi-Weekly Status Report Regarding Management Cease-Trade Order
VANCOUVER, BC / ACCESSWIRE / December 12, 2019 / Eastwest Bioscience Inc. ("Eastwest" or the "Corporation") provides this bi-weekly default status report in accordance with National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"). In its initial default announcement of November 29, 2019 (the "Default Notice"), the Corporation announced the delay in the filing of its audited annual financial statements for the year ended July 31, 2019 (the "2019 Annual Financial Statements") and related management discussion and analysis and certifications (collectively, the "Annual Filings") by the filing deadline of November 28, 2019. As previously announced, the Corporation applied for and was granted management cease trade orders in respect of the delayed Annual Filings (the "MCTO") by the British Columbia Securities Commission and the Financial and Consumer Affairs Division of Saskatchewan which prohibit the chief financial officer and the chief executive officer from trading in the Corporation's securities for so long as there are filings that are outstanding under applicable securities laws.
- ACCESSWIRE
Default Announcement
VANCOUVER, BC / ACCESSWIRE / November 29, 2019 / Eastwest Bioscience Inc. ("Eastwest" or the "Corporation") provides this default announcement indicating Eastwest's anticipated failure to file its annual financial statements for the year ended July 31, 2019 and related management discussion and analysis and certifications (collectively, the "Financial Statements") before the prescribed filing deadlines. The Corporation acquired Sangster's Health Centres ("Sangster's") with three subsidiaries on November 30, 2018.
- ACCESSWIRE
EastWest Bioscience Continues Expansion into the US market with the Construction on its CBD Processing and Bottling Line Nearing Completion
LEBANON, KY / ACCESSWIRE / November 27, 2019 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that, further to its News Release on June 20th, the Company is pleased to announce that construction is nearing completion on its CBD processing and bottling line in Lebanon, Kentucky. The CBD manufacturing line is part of its 50/50 joint venture with Azema Sciences through its US division, EastWest Science USA ("EastWest USA") and is targeted to be completed by December 15, 2019. The Joint Venture provides EastWest USA with continuous supply of premium CBD, as it is developing value added CBD consumer goods for the US market for the pet, skin care, functional food and supplement categories.
- ACCESSWIRE
InnerScope Hearing Technologies Inc. (OTCQB: INND) Establishes a Distribution, Warehousing, and Manufacturing Agreement in Canada and the United States with EASTWEST BIOSCIENCE INC. (TSX.V: EAST)
EASTWEST BIOSCIENCE INC. and InnerScope Hearing Technologies Inc. have entered into an Agreement for both companies to establish distribution and marketing rights to include warehousing and distribution ...
- GlobeNewswire
InnerScope Hearing Technologies (OTCQB: INND) Establishes a Distribution, Warehousing, and Manufacturing Agreement in Canada and the United States with EASTWEST BIOSCIENCE (TSX.V: EAST)
ROSEVILLE, Calif. and VANCOUVER, B.C., Nov. 06, 2019 -- via OTC PR WIRE -- InnerScope Hearing Technologies Inc. (OTCQB: INND) ("InnerScope") a manufacturer and.
- Simply Wall St.
Could The EastWest Bioscience Inc. (CVE:EAST) Ownership Structure Tell Us Something Useful?
A look at the shareholders of EastWest Bioscience Inc. (CVE:EAST) can tell us which group is most powerful...
- ACCESSWIRE
EastWest Bioscience Continues Expansion in US with Its First Production Run of CBD Pet Products
LEBANON, KN / ACCESSWIRE / October 30, 2019 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that, further to its News Release on July 23rd, the Company has completed the first production run of its CBD Pet Treats for the US Market. The premium CBD used in these CBD pet treats was supplied and produced through its joint venture partnership with Azema Sciences at its facility in Lebanon, Kentucky, USA.
- ACCESSWIRE
EastWest Bioscience Signs Distribution and Broker Deal with Rise North America Based in the United States
VANCOUVER, BC / ACCESSWIRE / September 10, 2019 / EastWest Bioscience (the “Company” or “EastWest”) (EAST.V) announces that it has signed a distribution and broker agreement with RISE North America (“RISE NA”) headquartered in Annapolis, MD. Since it was founded in 2016, EastWest continues to grow as a high-quality producer, manufacturer and distributor of multiple lines of premium health and hemp products.
- Simply Wall St.
Easy Come, Easy Go: How EastWest Bioscience (CVE:EAST) Shareholders Got Unlucky And Saw 70% Of Their Cash Evaporate
It's not a secret that every investor will make bad investments, from time to time. But it should be a priority to...
- ACCESSWIRE
EastWest Bioscience to Enter the People's Republic of China with Its Full Line of Hemp-Based Products
VANCOUVER, BC / ACCESSWIRE / August 15, 2019 / EastWest Bioscience (the “Company” or “EastWest”) (EAST.V) announces that it is in the final stages of obtaining it’s Business License to sell products into the People’s Republic of China through a strategic new partnership with Diverse Global Service (DGS), based in Chengdu Area of China (Sichuan) Pilot Free Trade Zone, who are both EastWest’s consultants and brokers. Chengdu has a diverse economy highlighting the food industry, IT and automotive manufacturing. It is one of the most important economic centers in Western China.
- ACCESSWIRE
EastWest Bioscience Signs Letter of Intent with Pet Tonics.
VANCOUVER, BC / ACCESSWIRE / August 1, 2019 / EastWest Bioscience (the “Company” or “EastWest”) (EAST.V) has signed an LOI with Pet Tonics, LLC, DBA Paws Effect (“Paws”), located in Coppell, TX USA (pawseffect.com). Partnering with strong brands is a significant part of EastWest’s overall strategy to ensure a larger footprint in the retail landscape in Canada, the USA, and Asia. Pet Tonics’ current products include CBD biscuits, balms, and tinctures.
- ACCESSWIRE
EastWest Bioscience Announces Grant of Stock Options
VANCOUVER, BC / ACCESSWIRE / July 24, 2019 / EastWest Bioscience (the “Company” or “EastWest”) (EAST.V) announces that it has granted stock options (“Options”) to acquire up to 3,792,500 common shares of the Company, 1,125,000 of which were granted to directors and officers of the Company. Each of the Options vested immediately, are exercisable for a five-year term, expiring in 2024 and exercisable at a price of $0.15 per common share. On the last day that the Company's common shares traded prior to the granting of the Options, the closing price of the common shares on the TSX Venture Exchange was $0.08 per share.
- ACCESSWIRE
EastWest USA Received First Batch of Full Spectrum CBD Oil from Azema Sciences for CBD Pet Treats
VANCOUVER, BC / ACCESSWIRE / July 23, 2019 / EastWest Bioscience (the “Company” or “EastWest”) (EAST.V) announces that, further to its News Releases on April 26th and June 25th, 2019, that the Company has received the first batch of its Full Spectrum CBD Oil for its initial pet orders for the US Market from its preferred supply and distribution Joint Venture with Azema Sciences out of its facility in Lebanon, Kentucky. Initially, the +CBD Chill Dog and +CBD Quick Cat will be sold through the company’s Kentucky based distribution arm, EastWest Science USA. “The Company continues to move forward at a rapid pace.
- Simply Wall St.
How Financially Strong Is EastWest Bioscience Inc. (CVE:EAST)?
While small-cap stocks, such as EastWest Bioscience Inc. (CVE:EAST) with its market cap of CA$6.1m, are popular for...
- ACCESSWIRE
EastWest Bioscience Reports Third Quarter 2019 Financial Results
VANCOUVER, BC / ACCESSWIRE / July 4, 2019 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) expands on its vision, strategy, and outlook for the future and comments on its 3Q financial results for the three months ended April 30, 2019. "US Approval was a tremendous achievement this quarter," explains Rodney Gelineau, CEO of EastWest Bioscience. Eastwest concluded its Joint Venture agreement with Azema Sciences, allowing it to start the production of CBD from its Kentucky facility, for its line of consumer products.
- ACCESSWIRE
EastWest Science USA Signs Mutual US Distribution Agreement with CBD Manufacturer GM Health Wholesale
VANCOUVER, BC / ACCESSWIRE / June 27, 2019 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that its subsidiary EastWest Science USA has signed a mutual distributor agreement with GM Health Wholesale ("GM Health") (www.gmhempco.com), a Kentucky company and a leading manufacturer and wholesaler of CBD Tinctures, Creams, Salves and Capsules. Under the terms of this agreement GM Health will become a distributor of EastWest's products and EastWest will become a global distributor for GM Health's all-natural CBD products.
- ACCESSWIRE
EastWest Bioscience Starts Production of CBD Pet Treats for the US Market
VANCOUVER, BC / ACCESSWIRE / June 25, 2019 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that, further to its News Release on April 26th, 2019, that the Company has started production of CBD infused Chill Dog and Quick Cat for the US Market. +CBD Chill Dog and +CBD Quick Cat will be sold through the company's Kentucky based distribution arm, EastWest Science USA. EastWest is working with distributors in the US for product launch pre-orders.
- ACCESSWIRE
EastWest Bioscience Continues Expansion in Western Canada Through Avafina Pet Products
VANCOUVER, BC / ACCESSWIRE / June 24, 2019 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that it has partnered with Avafina Pet Products ("Avafina") (www.avafinapet.com) to distribute its Natural Pet Science line of pet treats into more than 300 stores across Western Canada. Avafina's passionate and knowledgeable sales professionals, along with their distribution centre in Coquitlam, BC, provides a strategic distribution and sales partnership into the independent and retail chain channel for EastWest. Avafina's customer base includes strong independent pet food retailers along with some of the largest growing pet chains in Canada.
